Align Technology Inc (Align) is a medical device company that develops orthodontic products and software for dental professionals. The company serves the orthodontic and restorative dentistry industries. The company provides various technological products including Invisalign clear aligners for the treatment of malocclusions, Vivera retainers for retention, iTero intraoral scanners and services for dentistry, and exocad computer-aided design and computer-aided manufacturing software for dental laboratories and dental practitioners. It also offers an integrated suite of proprietary technologies and services known as the Align Digital Platform, which is designed to provide an end-to-end solution for patients, consumers, orthodontists, general dental practitioners, and dental laboratories. The company markets products through a direct sales force and an extensive network of distributors across Asia Pacific, Latin America, Europe, the Middle East, and Africa.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Align's R&D arm focuses on establishing the Invisalign System as the standard method for treating malocclusion, iTero intraoral scanners as the preferred scanning technology for digital dental scans, and exocad CAD/CAM software as the solution of choice for dental labs. The company's research and development activities are directed toward developing digital technology innovations, accelerating product and clinical innovation, developing treatment planning and manufacturing process improvements, and researching future technologies, products, and software. The treatment capabilities of the Invisalign System have been demonstrated by more than 800 peer-reviewed publications, and various clinical case studies and articles have been published highlighting the clinical applicability of Invisalign treatment. Similarly, studies have demonstrated the capabilities of iTero Lumina solutions, including advanced features such as NIRI technology. The company undertakes pre commercialization trials and testing of technological improvements to its products and manufacturing process. In September 2025, an enhanced clinical evidence webpage was launched, containing an expansive library of peer-reviewed clinical research publications and the Align Global Gallery, a searchable database of more than 1,500 real-world Invisalign treatment cases by doctors from around the world. The company also funds research in the field of orthodontics and dentistry through initiatives such as the Annual Research Award Program and donations to the American Association of Orthodontists Foundation. The R&D units of Align are located in the US and Israel. In FY2025, the company spent US$369.9 million on its R&D activities, which as a percentage of revenue stood at 9.2% and grew 1.6% YoY. As of December 2025, the company operated R&D units in the US and Israel. It also had 1,137 active US patents, 1,147 active foreign patents, and 1,070 pending global patent applications.